ChinaDaily Briefs

Daily Brief China: PCCW Ltd, Tencent, Zijin Gold, Guangzhou Innogen Pharmaceutical Group, Semiconductor Manufacturing International Corp (SMIC), Bitmain Technologies Ltd and more

In today’s briefing:

  • StubWorld: PCCW’s Tenacious NAV Premium
  • Tencent (700.HK) Q2 Earnings: Rally Into Earnings on Historically Low Volatility
  • Zijin Gold Pre-IPO: Spinoff to Cater to a Shiny Gold Market
  • Innogen (银诺医药) IPO: Fairly Valued at Best and Lack of Institutional Interests
  • SMIC (981.HK): 2Q25 Results in Line; 3Q25 May Offer Mild Upside, but GM Is Expected to Be Flattish.
  • The Equity Dispatch #47: Bitmain’s Quest for a Backdoor Listing: CANG and More


StubWorld: PCCW’s Tenacious NAV Premium

By David Blennerhassett

  • Despite the recent pullback, PCCW Ltd (8 HK) continues to trade at an unjustifiable premium to NAV.
  • Preceding my comments on PCCW/ HKT Ltd (6823 HK) are the current setup/unwind tables for Asia-Pacific Holdcos.
  • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

Tencent (700.HK) Q2 Earnings: Rally Into Earnings on Historically Low Volatility

By John Ley

  • Tencent approaches earnings with low volatility and steady outperformance versus HSI.
  • Volatilities are historically low with an earnings release on tap.  
  • Options market expects a modest move despite recent Tencent momentum.

Zijin Gold Pre-IPO: Spinoff to Cater to a Shiny Gold Market

By Nicholas Tan

  • Zijin Gold (2579355D HK) is looking to raise up to US$2.0bn in its upcoming Hong Kong IPO.
  • It is a global leading gold mining company formed by combining all of the gold mines of Zijin Mining, located outside of China.
  • In this note, we look at the firm’s past performance.

Innogen (银诺医药) IPO: Fairly Valued at Best and Lack of Institutional Interests

By Ke Yan, CFA, FRM

  • Innogen, a China-based near-commercial stage biotech company, launched its IPO to raise at least USD 88 million via a Hong Kong listing.
  • In our previous note, we have examined the company’s core product, namely efsubaglutide alfa,  updates in various filings, and our thoughts on valuation.
  • In this note, we look at the deal term. We think the valuation is demanding and lacks institutional interest.

SMIC (981.HK): 2Q25 Results in Line; 3Q25 May Offer Mild Upside, but GM Is Expected to Be Flattish.

By Patrick Liao

  • Semiconductor Manufacturing International Corp (SMIC) (981 HK) reported in-line 2Q25 results, while its 3Q25 guidance appears somewhat cautious, particularly in terms of gross margin.
  • The Americas continued to contribute a low-teens percentage to revenue, accounting for 12.9% in 2Q25, while China and Eurasia comprised the remaining majority.
  • Our top questions for the upcoming SMIC’s 3Q25 earnings conference call.   

The Equity Dispatch #47: Bitmain’s Quest for a Backdoor Listing: CANG and More

By J Capital Research

  • Bitmain is taking control of listed proxy firms in the United States. That could mean that the mining results of some proxies are overstated, and investors should avoid those companies.
  • It would be easy for Bitmain, the Chinese chip designer with about 80% of the global market for Bitcoin mining gear and significant mining operations of its own,¹ to report the same mining results for more than one company.
  • Many of these proxies pay Bitmain to mine on their behalf. Since Bitmain remains private, it has no responsibility to report related-party transactions.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars